2018 SGO Annual Meeting Presentations/Talks/Sessions:

Randomized Phase II Trial of Carboplatin-paclitaxel Versus Carboplatin-paclitaxel-trastuzumab in Uterine Serous Carcinomas That Overexpress Her2/Neu (NCT01367002)

Predictive Biomarkers of Endometrial Cancer Response: Results from NRG Oncology/ Gynecologic Oncology Group Study 86P
Douglas A Levine, Virginia Filiaci, Don S Dizon, Jay W Carlson, Matthew A Powell, Angeles Alvarez Secord, Krishnansu S Tewari, David P Bender, David M O'Malley, Ashley Stuckey, Kathleen Moore, Summer B Dewdney, JianJiong Gao, Fanny Dao, Robert A Soslow, Heather Lankes, Carol Aghajanian

Targeting the TIE2 Pathway with Novel Small Molecule VE-PTP Inhibitor, AKB-9785, in High-grade Serous Ovarian Cancer

*Research by Dr. Cobb, former Duke Ob/Gyn fellow, was developed based on research done by Dr. Secord that was supported by a grant through the Charles B. Hammond Research Fund.

The Affordable Care Act Reduced Racial and Socioeconomic Disparities in Access to Health Insurance Among Women Diagnosed with a Gynecologic Malignancy.
H.A. Moss, L.J. Havrilesky and J. Chino

Bevacizumab, TKI, or PARPi? A Targeted Approach Using Composite Value-based Endpoints and Biomarkers to Individualize Care for Platinum-sensitive Recurrent Ovarian Cancer (PSROC)
Are FDA-approved PARPi Cost-effective as Maintenance Treatment of Platinum-sensitive Recurrent Ovarian Cancer?
J.A. Dottino¹, H.A. Moss², K.H. Lu¹, A.A. Secord³ and L.J. Havrilesky²

Can the ASCO Alternative Payment Model Achieve Cost Savings in Ovarian Cancer Care?
H.A. Moss¹, M. Dinan², M.V. Georgieva², L.H. Hendrix² and L.J. Havrilesky¹
J.R. Foote, A. Alvarez-Secorda, M.I. Liangb, J.A. Ehrismana, M. Wuc, D.E. Cohnd, E. Jewellc and L.J. Havrileskya. aDuke University Medical Center, Durham, NC, USA, bDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA, cMemorial Sloan Kettering Cancer Center, New York, NY, USA, dThe Ohio State University, James Cancer Hospital, Columbus, OH, USA.

Evidence for Synthetic Lethality between Bevacizumab and Chemotherapy in Advanced, p53 Null Endometrial Cancers, Scientific Plenary Presentation:

Authors Carol A. Aghajanian Weill, Cornell Medical College; Author David P. Bender, University of Iowa Hospitals and Clinics; Eric Devor, University of Iowa Hospitals and Clinics; Summer B. Dewdney, Rush University Medical Center; Virginia L. Filiaci Gynecologic Oncology Group Statistical and Data Center; Jeffrey M. Fowler, The Ohio State University James Cancer Hospital, Kimberly K. Leslie, University of Iowa Hospitals and Clinics; Douglas A. Levine, NYU Langone Health; Adrienne Rose Mallen Moffitt Cancer Center-University of South Florida; Xiangbing Meng University of Iowa Hospitals and Clinics; Kathleen N. Moore, The University of Oklahoma Health Sciences Center; Matthew A. Powell, Washington University School of Medicine in St. Louis; Angeles Alvarez Secord, Duke Cancer Institute; Ashley R. Stuckey, Women & Infants Hospital, Brown University; Krishnansu S. Tewari, University of California Irvine Medical Center; Kristina Thiel; University of Iowa Carver College of Medicine.

Plenary Presentation:
The FILM Trial: A Randomized Phase III Multicenter Study Assessing Near Infrared Fluorescence in the Identification of Sentinel Lymph Nodes (SLN)

Dr. Laura Havrilesky moderated a session on Healthcare Economics.

Dr. Noah Kauff was Course Director for Sunrise Session III: Cancer Genetics, titled One Homologous Recombination Gene is Not Like Another.

Dr. Allison Puechl presented A Strategy for Early Implementation of Palliative Care and Hospice in Clinical Practice: A QI Initiative

Dr. Paula Lee was moderator for the session Adding to Your Palliative Care Toolbox: Strategies for Early Implementation, How to Teach Goals of Care Discussions, and Physician Assisted Suicide